GeneDx Holdings Corp. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company achieved total revenue of $102.3 million, marking a 17% increase from $87.1 million in the same period last year. Diagnostic test revenue specifically rose by 18% to $101.3 million, driven by a 34% increase in test volumes, although this was partially offset by a 5% decline in average reimbursement rates. The gross profit for the quarter was $68.2 million, up from $58.5 million, reflecting the increased test volumes.

However, the company also faced challenges, reporting a net loss of $63.3 million, a substantial increase from a loss of $6.5 million in the prior year. This loss was exacerbated by a $31.3 million impairment charge related to the goodwill and intangible assets of its Fabric Genomics reporting unit. Research and development expenses surged by 57% to $19.8 million, primarily due to increased staffing and costs associated with the Fabric Genomics acquisition. Selling, general, and administrative expenses also rose by 48% to $74.6 million, reflecting investments in the commercial team and increased operational costs.

Operationally, GeneDx reported a total of 27,488 exome and genome tests resulted during the quarter, which represented 50% of all test results, compared to 20,562 tests, or 40%, in the same quarter of 2025. The company continues to focus on expanding its customer base and increasing the adoption of its services, particularly in the genomic testing market. The acquisition of Fabric Genomics is expected to enhance its capabilities in rare disease and hereditary risk testing, although the integration has presented challenges.

In terms of liquidity, GeneDx had cash and cash equivalents of $93.9 million as of March 31, 2026, down from $105 million at the end of 2025. The company also secured a $100 million term loan from Blackstone, which it used to repay existing debts. Looking ahead, GeneDx aims to leverage its genomic database and expand its market presence, although it acknowledges the risks associated with reimbursement processes and the competitive landscape in the genomics sector. The company remains committed to innovation and operational efficiency as it navigates these challenges.

About GeneDx Holdings Corp.

GeneDx Holdings specializes in genetic testing and genomic interpretation for rare and complex diseases. Utilizing exome and whole genome sequencing, the company provides diagnostic solutions, data analysis, and interpretation services to healthcare providers, researchers, and biopharma partners. Its industry-leading dataset and advanced bioinformatics enable accurate, scalable, and actionable genetic insights, primarily serving pediatric and rare disease markets worldwide.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.